Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Histrelin Acetate

FDA-approved product (injectable, injection), marketed as Supprelin, Supprelin La, Vantas.

Registered studies
13
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Histrelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

13registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Histrelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Histrelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

    NCT06378866 · start 2024-06-03

    Registered record
    Registry ID
    NCT06378866
    Conditions
    Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma
    Interventions
    Abiraterone; Apalutamide; Biospecimen Collection; Bone Scan; Computed Tomography; Darolutamide; Degarelix; Enzalutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Prednisone; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Radiation Therapy; Image-Guided Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-03
    Completion
    2031-02-28
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma
    InterventionAbiraterone; Apalutamide; Biospecimen Collection; Bone Scan +17 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

    NCT05149131 · start 2022-01-17

    Registered record
    Registry ID
    NCT05149131
    Conditions
    Metastatic Castration-sensitive Prostate Cancer
    Interventions
    ADT (Eligard®*) with or without treatment intensification
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-17
    Completion
    2022-08-16
    Enrolment
    960

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-sensitive Prostate Cancer
    InterventionADT (Eligard®*) with or without treatment intensification
    PhaseNot recorded
    Registry statusCompleted

  • Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

    NCT05050084 · start 2021-12-06

    Registered record
    Registry ID
    NCT05050084
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Bicalutamide; Buserelin; Darolutamide; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-12-06
    Completion
    2031-11-11
    Enrolment
    2,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionBicalutamide; Buserelin; Darolutamide; Degarelix +7 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    NCT04787744 · start 2021-07-01

    Registered record
    Registry ID
    NCT04787744
    Conditions
    Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer
    Interventions
    PET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide; Degarelix & Relugolix; ADT + Docetaxel +/- prednisone; ADT + Abiraterone + Prednisone; ADT + Abiraterone + Methylprednisolone; ADT + Apalutamide; ADT + Enzalutamide; Prostate-directed Radiation for De novo oligometastatic prostate cancer
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2021-07-01
    Completion
    2029-03-30
    Enrolment
    464

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer +2 more
    InterventionPET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin +8 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

    NCT04513717 · start 2021-01-21

    Registered record
    Registry ID
    NCT04513717
    Conditions
    Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-21
    Completion
    2038-12-31
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Skeletal Health and Bone Marrow Composition Among Youth

    NCT04203381 · start 2020-09-15

    Registered record
    Registry ID
    NCT04203381
    Conditions
    Gender Dysphoria in Children; Puberty; Bone Development
    Interventions
    GnRH Agonist
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-09-15
    Completion
    2026-03-30
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGender Dysphoria in Children; Puberty; Bone Development
    InterventionGnRH Agonist
    PhaseNot applicable
    Registry statusTerminated

  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025 · start 2018-09-24

    Registered record
    Registry ID
    NCT03678025
    Conditions
    Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone; Bicalutamide; Degarelix; Docetaxel; Flutamide; Goserelin Acetate; Histrelin Acetate; Leuprolide Acetate; Nilutamide; Orchiectomy; Prednisone; Quality-of-Life Assessment; Radiation Therapy; Radical Prostatectomy; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-09-24
    Completion
    2031-10-01
    Enrolment
    1,273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionAbiraterone; Bicalutamide; Degarelix; Docetaxel +11 more
    PhasePhase 3
    Registry statusRecruiting

  • The Relation of GnRH Treatment to QTc Interval in Transgender Females

    NCT03078829 · start 2017-05-01

    Registered record
    Registry ID
    NCT03078829
    Conditions
    Gender Dysphoria
    Interventions
    Treatment with a GnRh agonists
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-05-01
    Completion
    2017-08-21
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGender Dysphoria
    InterventionTreatment with a GnRh agonists
    PhaseNot recorded
    Registry statusTerminated

  • Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

    NCT02278185 · start 2015-11-11

    Registered record
    Registry ID
    NCT02278185
    Conditions
    Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    Enzalutamide; leuprolide acetate; goserelin acetate; histrelin acetate; triptorelin; degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-11-11
    Completion
    2024-07-18
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
    InterventionEnzalutamide; leuprolide acetate; goserelin acetate; histrelin acetate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Vantas Implant Retrieval Study

    NCT01013025 · start 2006-07

    Registered record
    Registry ID
    NCT01013025
    Conditions
    Prostate Cancer
    Interventions
    Ultrasound or CT or MRI to locate implant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionUltrasound or CT or MRI to locate implant
    PhaseNot recorded
    Registry statusCompleted

  • Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

    NCT00779103 · start 2004-09

    Registered record
    Registry ID
    NCT00779103
    Conditions
    Central Precocious Puberty
    Interventions
    Histrelin Subcutaneous Implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-09
    Completion
    2012-04
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionHistrelin Subcutaneous Implant
    PhasePhase 3
    Registry statusCompleted

  • Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

    NCT01394263 · start 2000-05

    Registered record
    Registry ID
    NCT01394263
    Conditions
    Prostate Cancer; Adenocarcinoma of the Prostate
    Interventions
    Histrelin hydrogel implant; Zoladex goserelin implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-05
    Completion
    2003-12
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Adenocarcinoma of the Prostate
    InterventionHistrelin hydrogel implant; Zoladex goserelin implant
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

    NCT01697384 · start 2000-04

    Registered record
    Registry ID
    NCT01697384
    Conditions
    Prostate Cancer; Adenocarcinoma of the Prostate
    Interventions
    histrelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-04
    Completion
    2004-10
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Adenocarcinoma of the Prostate
    Interventionhistrelin acetate
    PhasePhase 3
    Registry statusCompleted